Evidence map›Paper›PMID 41749201›Full record

ArticleJournal of nanobiotechnology2026

PD1 cell membrane-coated Ru(ll)-Pt(lV) complex nanoparticles inhibit liver metastatic melanoma via cascade immune activation.

Cong Huang, Thuy Thu Phann, Feijun OuYang, Duanzhe Zhou, Pei Guo, Yuqing Wang, Yun Huang, Tian Zeng, Qing Gao, Hua Wei and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Cong Huang *Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study, School of Pharmaceutical Science, Hengyang Medical School, University of South China, Hengyang, 421001, China.
Thuy Thu Phann *Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study, School of Pharmaceutical Science, Hengyang Medical School, University of South China, Hengyang, 421001, China.
Feijun OuYangHunan Province Cooperative Innovation Center for Molecular Target New Drug Study, School of Pharmaceutical Science, Hengyang Medical School, University of South China, Hengyang, 421001, China.
Duanzhe Zhou *Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study, School of Pharmaceutical Science, Hengyang Medical School, University of South China, Hengyang, 421001, China.
Pei GuoHunan Province Cooperative Innovation Center for Molecular Target New Drug Study, School of Pharmaceutical Science, Hengyang Medical School, University of South China, Hengyang, 421001, China.
Yuqing WangHunan Province Cooperative Innovation Center for Molecular Target New Drug Study, School of Pharmaceutical Science, Hengyang Medical School, University of South China, Hengyang, 421001, China.
Yun HuangHunan Province Cooperative Innovation Center for Molecular Target New Drug Study, School of Pharmaceutical Science, Hengyang Medical School, University of South China, Hengyang, 421001, China.
Tian ZengHunan Province Cooperative Innovation Center for Molecular Target New Drug Study, School of Pharmaceutical Science, Hengyang Medical School, University of South China, Hengyang, 421001, China.
Qing GaoHunan Province Cooperative Innovation Center for Molecular Target New Drug Study, School of Pharmaceutical Science, Hengyang Medical School, University of South China, Hengyang, 421001, China.
Hua WeiHunan Province Cooperative Innovation Center for Molecular Target New Drug Study, School of Pharmaceutical Science, Hengyang Medical School, University of South China, Hengyang, 421001, China. weih@usc.edu.cn.
Cui-Yun YuAffiliated Hospital of Hunan Academy of Chinese Medicine, Hunan Academy of Chinese Medicine, Changsha, 410013, China. yucuiyunusc@hotmail.com.

Funding

National Natural Science Foundation of China,China 82373826
6 · The paper itself

Abstract

Chemotherapy and photodynamic therapy (PDT) can indirectly increase T cell infiltration in metastatic melanoma by inducing immunogenic cell death (ICD) effects that activate the innate immune system. However, this indirect adaptive immune activation show limited efficacy in treating liver metastatic melanoma, mainly because the presence of abundant inimmunosuppressive cells within liver metastases leads to impaired function of the ICD-activated effector T cells. Therefore, to combine indirectly increased T cell infiltration with directly enhanced T cell killing function for initiating a cascaded immune process, we report herein an engineered PD1 cell membrane-coated Ru(ll)-Pt(lV) complex nanoparticle (Ru-Pt-Ru@PD1) for integrated chemo/PDT/ICB therapy. Ru-Pt-Ru@PD1 enhances the accumulation of Ru and Pt in tumors to induce the ICD effects and activate innate and adaptive immunity. Moreover, the engineered PD1 cell membrane continuously blocks the PD1/PDL1 immunosuppressive axis, a key advantage over common monoclonal antibodies that are rapidly captured by macrophage receptor. Ultimately, Ru-Pt-Ru@PD1 increases T cells infiltration and and restores the killing function of these T cells, enabling a cascaded and sustained immune response. Ru-Pt-Ru@PD1 significantly suppressed both proximal melanoma and distal liver cancer in a mouse model bearing melanoma and liver cancer simultaneously, and prevent primary and metastatic tumors with a high tumor inhibition rate (TIR) of 92.2% for the primary melanoma and significantly inhibited metastasis of melanoma in the liver and other organs, in a melanoma metastasis mouse model. Overall, this study provides an effective method for cascaded amplification of antitumor immune effects, demonstrating the clinical potential for metastatic melanoma treatment.

Indexed as

Liver NeoplasmsMelanomaNanoparticlesProgrammed Cell Death 1 ReceptorRutheniumAnimalsCell Line, TumorCell MembraneFemaleHumansMelanoma, ExperimentalMiceMice, Inbred C57BLPhotochemotherapyPlatinumT-LymphocytesPlatinumProgrammed Cell Death 1 ReceptorRutheniumCascade immune activationEngineered PD1 cell membraneMetastatic melanomaPDT

Identifiers

PMID41749201
PMCPMC13041168

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.